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Abstract 27 
As resistance to artemisinins (current frontline drugs in malaria treatment) emerges in south East 28 
Asia, there is an urgent need to identify the genetic determinants and understand the molecular 29 
mechanisms underpinning such resistance.  Such insights could lead to prospective interventions to 30 
contain resistance and prevent the eventual spread to other malaria endemic regions. Artemisinin 31 
reduced susceptibility in South East Asia (SEA) has been primarily linked to mutations in P. 32 
falciparum Kelch-13, which is currently widely recognised as a molecular marker of artemisinin 33 
resistance. However, 2 mutations in a ubiquitin hydrolase, UBP-1, have been previously associated 34 
with artemisinin reduced susceptibility in a rodent model of malaria and some cases of UBP-1 35 
mutation variants associating with artemisinin treatment failure have been reported in Africa and 36 
SEA.  In this study, we have employed CRISPR-Cas9 genome editing and pre-emptive drug pressures 37 
to test these artemisinin susceptibility associated mutations in UBP-1 in P. berghei sensitive lines in 38 
vivo. Using these approaches, we have shown that the V2721F UBP-1 mutation results in reduced 39 
artemisinin susceptibility, while the V2752F mutation results in resistance to chloroquine and 40 
moderately impacts tolerance to artemisinins. Genetic reversal of the V2752F mutation restored 41 
chloroquine sensitivity in these mutant lines while simultaneous introduction of both mutations 42 
could not be achieved and appears to be lethal. Interestingly, these mutations carry a detrimental 43 
growth defect, which would possibly explain their lack of expansion in natural infection settings. Our 44 
work has provided independent experimental evidence on the role of UBP-1 in modulating parasite 45 
responses to artemisinin and chloroquine under in vivo conditions.   46 
 47 
 48 
 49 
 50 
 51 
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Introduction 52 
Artemisinins (ARTs) in artemisinin combinational therapies (ACTs) remain the mainstay of malaria 53 
treatment globally and thus far remain mostly effective in sub-Saharan Africa where most of the 54 
disease burden occurs (1). However, ART (and even ACT) resistance has emerged in SEA with a risk of 55 
spreading which is seriously threatening recent gains achieved in malaria control (2, 3). ART 56 
resistance is thought to be primarily conferred by specific mutations in the Plasmodium falciparum 57 
Kelch-13 (PfKelch13) gene, and such mutations are currently almost endemic in most parts of SEA (1, 58 
4, 5). Phenotypically, these mutations are associated with delayed parasite clearance rates in vivo 59 
and reduced susceptibility of ring stage parasites in vitro in ring stage survival assays (RSA) (3, 6). 60 
Interestingly, the prevalence of PfKelch13 mutations remains low outside SEA (7) where the few 61 
observed PfKelch13 polymorphisms in sub-Saharan Africa do not associate with treatment failure 62 
and/or delayed parasite clearance rates (8). Moreover, large-scale genome wide association studies 63 
have revealed that polymorphisms in other genes such as multidrug resistance protein 2, ferredoxin 64 
and others also associate with delayed parasite clearance rates in SEA (9). More recently, mutations 65 
in an independent gene, P. falciparum coronin (PfCoronin) have been shown to confer enhanced 66 
survival of ring stage parasites to dihydroartemisinin (DHA) (10). Deconvoluting the geographic 67 
complexities of ART resistance, genetic determinants and molecular mechanism involved would thus 68 
provide an avenue to contain or rescue the emergent ART resistance through efficient surveillance 69 
and/or suitable combinational therapies. 70 
 71 
Mutations in a ubiquitin hydrolase, UBP-1 (HAUSP or USP7 close homologue), were previously 72 
identified to modulate susceptibility to ART and chloroquine (CQ) in the rodent infectious malaria 73 
parasite, Plasmodium chabaudi, after sequential experimental evolution and selection with a series 74 
of antimalarial drugs (11). The reported drug resistant phenotypes emerged from in vivo passage 75 
and exposure of P. chabaudi drug sensitive AS line to sub-lethal doses of pyrimethamine, CQ, 76 
mefloquine and ARTs (11-13). Interestingly, in these P. chabaudi lineages, CQ resistance at 15mg/kg 77 
emerged first and from this uncloned line, whole genome sequencing revealed 2 UBP-1 mutations 78 
(V2697F and V2728F) which were associated with the resistance phenotype (13, 14). Further 79 
selection of this uncloned CQ resistant line generated lines with different drug resistant profiles: 1) a 80 
line resistant to 15mg/kg mefloquine 2) a line resistant to CQ at 30mg/kg  3) a line resistant to up to 81 
300mg/kg ART which was selected from the CQ 30mg/kg resistant line  4) a line resistant to up to 82 
60mg/kg artesunate.  Upon further cloning and genome sequencing of these lines, it was found that 83 
the UBP-1 V2728F mutation was common in the ART, CQ (30mg/kg) and mefloquine resistant lines 84 
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while the V2697F mutation only fixated upon artesunate selection (11, 12, 14). Due to the 85 
complexity of the selection procedure with multiple drugs, it has been difficult to confidently 86 
associate these UBP-1 mutations with ART and CQ susceptibility in the absence of appropriate 87 
reverse genetics approaches. Recently, these mutations have been introduced into UBP-1 in P. 88 
falciparum and the V2721F equivalent has been shown to associate with increased DHA RSA survival 89 
with no CQ resistance phenotype while the V2728F orthologue appeared to have no ART or CQ 90 
resistance profiles (15). More interestingly, UBP-1 mutation variants have been associated with ARTs 91 
decreased effectiveness in Africa and some parts of Asia (16-19). 92 
 93 
In our present study, we have successfully engineered UBP-1 candidate mutations in an independent 94 
rodent model, P. berghei using a CRISPR-Cas9 genome editing system. We provide a causal link to 95 
the ART and CQ reduced susceptibility profiles of these mutant lines both in vitro and in vivo. We 96 
have also characterised their relative fitness as compared to the wild type non-mutant parasites. 97 
 98 
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Materials and methods 99 
CRISPR Cas9 generation of UBP-1 mutant lines 100 
Primary vectors 101 
The Cas9 expressing plasmid ABR099 was used for targeted nucleotide replacement at the UBP-1 102 
locus. ABR099 (Figure 1A) contains the Cas9 endonuclease driven by the Pb Ef-1α promoter, a Cas9 103 
binding scaffold, a site for cloning the guide RNA (sgRNA) driven by the Plasmodium yoelii U6 104 
promoter, an hdhfr cassette (for pyrimethamine drug resistance selection) and a linker site for 105 
insertion of homologous repair templates. sgRNAs targeting the UBP-1 locus were designed using 106 
the web based eukaryotic pathogen CRISPR guide RNA/DNA design tool (http://grna.ctegd.uga.edu/) 107 
(20) by directly inputting the sequence of interest.  Primary vectors containing the sgRNA of interest 108 
were generated by annealing oligonucleotide pairs (GU4788+GU4789 and GU5206+GU5207, 109 
supplementary Table 1) encoding the guide sequence and cloning them in the dual Esp3I sites 110 
upstream of the Cas9 binding domain of the vector ABR099. These plasmids were called pG944 and 111 
pG960 for the GU4788+GU4789 and GU5206+GU5207 annealed guides respectively. 112 
Mutagenesis and generation of secondary vectors 113 
To generate the final vectors for editing the UBP-1 locus, 610bp of UBP-1 donor DNA 114 
(PBANKA_0208800) was PCR amplified using primers GU4786 and GU4787 (supplementary Table 1) 115 
designed to contain a HincII site at the 5’ end. The PCR product was purified, A-tailed and cloned into 116 
the TOPO 2.1 vector using the TOPO TA cloning kit (Invitrogen) according to manufacturer’s 117 
instructions. To mutate the UBP-1 locus, 3 primer sets (supplementary Table 1) complementary to 118 
the amplified UBP-1 PCR product were designed to contain specific nucleotide substitutions as 119 
follows: 1) a shielding primer (GU4783) containing three silent mutations mutating the sgRNA and 120 
PAM sites targeted by the GU4788+GU4789 sgRNA (to prevent Cas9 binding the donor templates 121 
and the edited loci in the mutant parasites) as well as introducing a BseYI restriction site for 122 
restriction site fragment polymorphism (RFLP) analysis  2) Primer sets carrying the mutations of 123 
interest;  V2721F mutation (GU4785) and V2752F (GU4784). A site directed mutagenesis of the 124 
cloned UBP-1 PCR product in the TOPO 2.1 vector was carried out using a QuikChange® multi-site 125 
directed mutagenesis kit (Agilent technologies) using the following primer combinations: 126 
GU4783+GU4784 for the V2752F single mutant and GU4783+GU4784+GU4785 for the double 127 
mutant. The resulting mutant fragments in the TOPO 2.1 vector were digested out and cloned into 128 
the linker site of the vector pG944 using the HincII restriction site to generate pG945 (single mutant) 129 
and pG946 (double mutant). For targeted mutation swapping and a second attempt to generate a 130 
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double mutant line, a second sgRNA (GU5206+GU5207) upstream of the V2721F mutation was 131 
designed and cloned into the ABR099 vector as described. Donor DNA was amplified from the 132 
G1808V2721F or pG946 vector to generate single or double mutation templates respectively using 133 
overlapping PCR as previously described (21). Briefly, internal complementary primers (GU5190 and 134 
GU5191, supplementary Table 1) carrying 3 silent mutations (2 for mutating the sgRNA and PAM of 135 
the GU5206+GU5207 sgRNA, 1 to introduce the SnaBI restriction site for RFLP analysis) were used to 136 
amplify 2 overlapping PCR products from the G1808V2721F DNA or pG946 plasmid upon linkage to 137 
HincII introducing outer primers GU5189 and GU4787 (supplementary Table 1). After gel purification, 138 
~50ng of the overlapping PCR fragments were used as templates in a second round of PCR using the 139 
two outer primers (GU5189 and GU4787) to generate donor fragments with mutations of interest. 140 
The resulting fragments were subsequently cloned into the pG960 vector at the linker site using the 141 
HincII restriction site to generate the vectors pG963 (silent mutations to GU5206+GU5207 sgRNA, 142 
V2721F mutation) and pG962 (silent mutations to GU5206+GU5207 sgRNA, V2721F and V2752F 143 
mutation). All PCR reactions were carried out using the high fidelity KAPA hifi PCR kit (Roche). 144 
Plasmids were verified by Sanger DNA sequencing prior to further use. 145 
P. berghei animal infections 146 
P. berghei parasites were maintained in female Theiler’s Original (TO) mice (Envigo) weighing 147 
between 25-30g. Parasite infections were established either by intraperitoneal injection (IP) of 148 
~200µl of cryopreserved parasite stocks or intravenous injections (IVs) of purified schizonts. 149 
Monitoring of parasitaemia in infected mice was done by examining methanol fixed thin blood 150 
smears stained in Giemsa (Sigma) or flow cytometry analysis of infected blood stained with Hoescht 151 
33342 (Invitrogen). Blood from infected mice was collected by cardiac puncture under terminal 152 
anaesthesia. All animal work was performed in compliance with UK home office licensing (Project 153 
reference: P6CA91811) and ethical approval from the University of Glasgow Animal Welfare and 154 
Ethical Review Body. 155 
 156 
 157 
 158 
 159 
 160 
Parasite lines and transfections 161 
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An 820 line that express green fluorescent protein (GFP) and red fluorescent protein (RFP) in male 162 
and female gametocytes respectively (22) was used for initial transfection experiments while the 163 
1804cl1 line that constitutively express mCherry throughout the life cycle (23) was used for growth 164 
competition assays as a control. ~10µg of episomal plasmid DNA from the vectors described above 165 
was transfected by mixing with Nycodenz purified schizonts and electroporated using the Amaxa 166 
Nucleofector Device II program U-o33 as previously described (24). Parasites were then immediately 167 
IV injected into a tail vein of mice. Positive selection of transfected parasites was commenced 24 168 
hours later by inclusion of pyrimethamine (Sigma) in drinking water. 169 
Genotype analysis of mutant lines 170 
Blood was collected from parasite infected mice by cardiac puncture under terminal anaesthesia and 171 
lysed by resuspension in 1X E-lysis buffer (Thermo). Parasite genomic DNA was extracted using the 172 
Qiagen DNeasy Blood and Tissue kit according to manufactures’ instructions. Genotype analysis of 173 
the transfected or cloned parasite lines was analysed, initially by a dual PCR-RFLP. PCR using exterior 174 
primers (GU4894+GU4895 or GU5186+GU4895) was used to amplify fragments from the DNA of the 175 
mutant lines followed by restriction digests with either BseYI or SnaBI restriction enzymes to verify 176 
successful editing of the UBP-1 locus. Transfection efficiencies were estimated by relative 177 
densitometric quantification of RFLP fragments by ImageJ2 (25). Further confirmation of the 178 
mutations was carried out by Sanger DNA sequencing. 179 
P. berghei in vitro culture and drug susceptibility assays 180 
For in vitro maintenance of P. berghei, cultures were maintained for one developmental cycle using 181 
a standardised schizont culture media containing RPMI1640 with 25mM hypoxanthine, 10mM 182 
sodium bicarbonate, 20 % foetal calf serum, 100U/ml Penicillin and 100μg/ml streptomycin. Culture 183 
flasks were gassed for 30 seconds with a special gas mix of 5% CO2, 5% O2, 90% N2 and incubated 184 
for 22-24 hours at 370C with gentle shaking, conditions that allow for development of ring stage 185 
parasites to mature schizonts. Drug assays to determine in vitro growth inhibition during the 186 
intraerythroctic stage were performed in these standard short-term cultures as previously described 187 
(26). Briefly, 1 ml of infected blood with a non-synchronous parasitaemia of 3-5% was collected from 188 
an infected mouse and cultured for 22-24 hours in 120 ml of schizont culture media. Schizonts were 189 
enriched from the cultures by Nycodenz density flotation as previously described (24) followed by 190 
immediate injection into a tail vein of a naive mouse. Upon IV injection of schizonts, they 191 
immediately rupture with resulting merozoites invading new red blood cells within minutes to obtain 192 
synchronous in vivo infection containing >90% rings and a parasitaemia of 1-2%. Blood was collected 193 
from the infected mice 2 hours post-injection and mixed with serially diluted drugs in schizont 194 
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culture media in 96 well plates at a final haematocrit of 0.5% in a 200µl well volume. Plates were 195 
gassed and incubated overnight at 370 C. After 22-24 hours of incubation, schizont maturation was 196 
analysed by flow cytometry after staining the infected cells with DNA dye Hoechst-33258. Schizonts 197 
were gated and quantified based on fluorescence intensity on a BD FACSCelesta or a BD LSR Fortessa 198 
(BD Biosciences, USA). To determine growth inhibitions and calculate half-inhibitory concentrations 199 
(IC50), quantified schizonts in no drug controls were set to correspond to 100% with subsequent 200 
growth percentages in presence of drugs calculated accordingly. Dose response curves were plotted 201 
in Graph-pad Prism 7. 202 
In vivo drug assays 203 
A modified Peters’ 4 day suppressive test was employed to assess in vivo drug responses and or 204 
resistance profiles in the wild type and mutant lines as previously described (27). Parasitaemia was 205 
initiated by IP inoculation of between 106-107 parasites followed by three daily consecutive drug 206 
doses initiated ~4 hours post inoculation. CQ was prepared at 50mg/ml in 1X PBS and diluted to 207 
working stock in 1X PBS while ART was prepared at 12.5mg/ml in a 1:1 mixture of DMSO and Tween® 208 
80 (Sigma) followed by a ten-fold dilution in sterile water to an injectable working solution. All drugs 209 
were delivered by IP and were prepared fresh immediately before injection. Parasitaemia was 210 
monitored daily by flow cytometry and analysis of methanol fixed Giemsa stained smears. 211 
In vivo growth competition assays 212 
Clonal mutant lines in the 820 background were mixed with the 1804cl1 line that constitutively 213 
express mCherry under the control of the hsp70 promoter at a 1:1 mixture and injected 214 
intravenously in mice. Parasitaemia in the competition mixtures was quantified by flow cytometry 215 
quantification of mCherry positive parasites for the 1804cl1 proportional percentage and by 216 
subtracting the total parasitaemia (Hoescht positive) from the mCherry positive proportion for the 217 
820 control and or mutant lines. Differentiation of the mCherry positive population from the RFP in 218 
the 820 line was carried out by applying flow compensation gating strategies (Supplementary Figure 219 
3).220 
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Results 221 
CRISPR-Cas9 engineered mutations in UBP-1 confer in vivo selective advantage to ART and CQ 222 
pressure in Plasmodium berghei. 223 
To experimentally demonstrate that UBP-1 mutations confer selective advantage upon ART pressure, 224 
we introduced P. chabaudi UBP-1 candidate mutation (V2697F and V2728F) equivalents 225 
(supplementary Figure 1) in the P. berghei 820 line using the CRISPR-Cas9 system developed and 226 
optimised in our lab (Figure 1A). Two plasmids were initially designed to either introduce the single 227 
mutation, V2752F (V2728F P. chabaudi equivalent) or both mutations, V2721F (V2697F P. chabaudi 228 
equivalent) and V2752F in an attempt to generate a double mutant (Figure 1A). Silent mutations to 229 
mutate the Cas9 cleavage site and introduce a restriction site (BseYI) were also introduced to 230 
prevent re-targeting of mutated loci by Cas9 for the former and diagnosis by RFLP for the latter 231 
(Figure 1A, 1B). Transfections of these plasmids into the 820 line yielded ~0.5% mutants for the 232 
V2752F mutant line (G1807, pG945) and ~23.00% mutants for the V2721F and V2752F double 233 
mutant line (G1808, pG946) as confirmed by RFLP analysis (BseYI digestion) of the edited UBP-1 loci 234 
(Figure 1B). Since the efficiency was too low to clone out the mutant lines by serial dilution, we 235 
attempted a pre-emptive drug selection with CQ and ART of the G1807 and G1808 lines to examine 236 
if selective enrichment of the mutant population could be achieved. Indeed, after infecting mice 237 
with the G1808 line and treating for three consecutive days with ART at 20mg/kg, the recrudescent 238 
parasite population on Day 9 was enriched to ~90 % mutant population as confirmed by RFLP 239 
analysis (Figure 1C, Supplementary Figure 2D).  Meanwhile, CQ at 15mg/kg also enriched the G1808 240 
line to ~80 %, relatively less compared to ART (Figure 1C). On the contrary, a very low-level mutant 241 
enrichment of the G1807 line (0.5% to 2.6%) was observed with CQ at 15mg/kg while ART did not 242 
produce any enrichment in the same line (0.5%). Interestingly, cloning of the G1808 ART enriched 243 
lines yielded six clones which were all single mutants positive for the V2721F mutation despite 244 
coming from a plasmid with donor templates that carried both the V2721F and V2752F mutations 245 
(Figure 1E, F). This suggests that the single V2721F mutation carrying parasites were predominant in 246 
the G1808 line (despite resulting from transfection with a plasmid carrying both mutations) and 247 
were selectively enriched by ART. These data also suggested that introducing both mutations into 248 
the same parasite could either be lethal or results in very unfit parasites that are easily cleared by 249 
the host during early growth following transformation. Indeed, bulk DNA sequence analysis of the 250 
G1808 uncloned line revealed the absence of traces for both mutations as only the V2721F with 251 
silent mutations were present (Supplementary Figure 2B). Sequence analysis of the G1808 line 252 
isolated after CQ challenge at 15mg/kg also confirmed specific enrichment for the V2721F mutation 253 
(supplementary Figure 2D) suggesting that despite being principally enriched by ART, the V2721F 254 
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mutation also modulates some resistance to CQ. Meanwhile, when we challenged the G1807 line 255 
(V2752F single mutation) with CQ at higher doses (20, 30, 50mg/kg), a recrudescent population was 256 
observed on Day 10 with CQ 30mg/kg (Figure 1D). The CQ 30mg/kg recrudescent parasites were 257 
enriched to ~61 % for the mutant population (Figure 1D, Supplementary Figure 2C) and were 258 
subsequently cloned. Sanger sequencing of G1808 ART enriched and G1807 CQ enriched clones 259 
confirmed the presence of the single V2721F and V2752F mutations respectively, as well as the Cas9 260 
cleavage silencing mutations and the silent mutations introducing the BseYI diagnostic restriction 261 
site (Figure 1F). 262 
 263 
The V2721F mutation confers observable reduced in vivo susceptibility to ARTs while the V2752F 264 
mutation confers resistance to CQ and low-level protection to ARTs. 265 
We next quantitated the drug response profiles of the G1808V2721F and G1807V2752F cloned lines (first 266 
clone in each of the lines) in vitro and in vivo using DHA, ART and CQ. In short term P. berghei in vitro 267 
drug assays, both the G1808V2721F and G1807V2752F parasites show no difference in sensitivity to DHA 268 
compared to the parental 820 line (Figure 2A, 2B). The lack of decreased drug sensitivity of both 269 
lines is consistent with the failure of the standard 72-hour drug assays to differentiate similar Kelch-270 
13 ART resistant parasites from sensitive lines in P. falciparum (3, 6). Meanwhile, a 1.8 fold increase 271 
in IC50 was observed for the G1807
V2752F line when challenged with CQ (Figure 2C) and not the G1808 272 
V2721F (Figure 2D).  However, rodent malaria parasites offer the advantage of experimental drug 273 
resistance assessment in vivo. Therefore, we profiled the in vivo drug responses of the mutant lines 274 
to parental ART, which with controlled parasite inocula has been shown to effectively suppress wild 275 
type parasites for up to 18 days following 100mg/kg dosing for three consecutive days (12). This is 276 
unlike with the ART derivative, and clinically relevant, artesunate which permits recrudescence in 277 
wild type rodent malaria parasites at doses as high as 300mg/kg within 14 days (28). This approach 278 
when applied to G1808V2721F demonstrated that this mutation does indeed confer enhanced in vivo 279 
tolerance to ARTs compared to the parental 820 line.   G1808V2721F parasites survive three 280 
consecutive doses of 75mg/kg ART with the recrudescent population appearing on day 9 after last 281 
dosing while 820 wild type parasites are effectively suppressed up to day 17 of follow-up (Figure 2E). 282 
Both the G1808V2721F and 820 lines survive 45mg/kg dose of ART with the former having a slightly 283 
faster recrudescence rate on day 7 while the latter recrudesces a day later (Figure 2E). Even though 284 
ART at 45mg/kg does not significantly separate wild type from mutant parasites, this could be due to 285 
the fitness cost that the V2721F mutation carries (Figure 3) which would explain their recrudescence 286 
at almost the same time as the wild type as they would require a slightly longer time to achieve 287 
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quantifiable parasitaemias. Both lines remain sensitive to 125mg/kg ART dose with no 288 
recrudescence observed up to day 17 (Figure 2E). In contrast, the G1807V2752F line is relatively 289 
resistant to CQ in vivo (Figure 2F), surviving three consecutive doses at 25mg/kg, with recrudescent 290 
parasites coming up on day 4 after the last dose as compared to the parental 820 line and the 291 
G1808V2721F lines which are sensitive and are effectively suppressed up to day 17. Interestingly, the 292 
G1807V2752F line also displays low level reduced susceptibility to ART at 75mg/kg dose, with parasites 293 
coming up on day 12, later than the G1808V2721F line (Figure 2F). These data confirm that the V2721F 294 
mutation confers protection from ART drug challenge while the V2752F mutation mediates 295 
resistance primarily to CQ and to some extent, a low-level protection to ARTs. The recrudescence of 296 
the wild type 820 and G1808V2721F at 45mg/kg ART is also in agreement with our previous findings, 297 
that P. berghei is less sensitive to ARTs, especially in the spleen and bone marrow which could be the 298 
source of recrudescent infection at relatively lower doses (29). 299 
 300 
Growth of parasites carrying UPB-1 V2752F and V2721F mutations is impaired  301 
The spread of drug resistance as is the case in most microbial pathogens is partly limited by 302 
detrimental fitness costs that accompany acquisition of such mutations in respective drug 303 
transporters, enzymes or essential cellular components. The G1807 and G1808 lines carrying UBP-1 304 
V2721F and V2752F mutations respectively were each grown in competition with a parental line 305 
expressing mCherry in vivo and shown to be characteristically slow growing (Figure 3A-C). 306 
Comparatively, the G1807V2752F mutation is severely impaired relative to the G1808V2721F being 307 
completely outcompeted by day 8. These data and the earlier failure to generate the double mutant 308 
(Figure 1) demonstrate that UBP-1 is an important (possibly essential) protein for parasite growth 309 
and that acquisition of resistance through mutation of UBP-1 confers mutation specific fitness costs. 310 
 311 
Reversal of the V2752F mutation restores CQ sensitivity in the G1807V2752F line while introduction 312 
of the V2721F in the same line appears to be lethal 313 
Drug pressure can select, in the long or short term, for mutations in sensitive parasite populations 314 
that would affect responses to the same drug. To further confirm that the phenotypes observed in 315 
our mutant lines were due to the V2721F or V2752F mutations and not possible secondary 316 
mutations which may have been acquired during the pre-emptive drug pressure, we attempted to 317 
reverse the V2752F mutation in the G1807V2752F line by swapping it to the V2721F genotype. This 318 
would allow us to determine if wild type CQ phenotypes can be restored in the G1807V2752F line while 319 
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at the same time assess if the ART susceptibility profiles of the G1808V2721F mutants could be 320 
reproduced in an independent line. Using a CRISPR Cas9 editing strategy similar to the one outlined 321 
above, a sgRNA targeting a region ~50bp upstream of the V2721F mutation was designed and cloned 322 
in the Cas9 expressing vectors (Figure 4A). 698bp of donor DNA (GU5189 + GU4787) containing the 323 
V2721F (for targeted mutation swap) or both the V2721F and V2752F mutations (for a forced 324 
introduction of the V2721F in the G1807V2752F background) was used to generate the vectors pG963 325 
and pG962 respectively (Figure 4A). Silent mutations mutating the PAM site as well as introducing a 326 
second restriction site, SnaBI, for RFLP analysis were also included. Transfection of the G1807V2752F 327 
line with pG963 and pG962 vectors successfully edited the UBP-1 loci generating the G1918 and 328 
G1919 lines respectively with ~88 % and ~79 % efficiency as confirmed by SnaBI RFLP analysis (Figure 329 
4A). Cloning and sequencing of the G1918 line revealed successful targeted mutation swap, 330 
introducing the V2721F mutation and re-editing of the 2752F to 2752V wild type genotype (Figure 331 
4B, 4C). Phenotype analysis of the G1918 clone line revealed a restored in vitro susceptibility to CQ 332 
similar to the 820 wild type and a similar DHA sensitivity (Figure 4D). Under in vivo conditions, the 333 
G1918cl1 line displayed a similar ART susceptibility profile at 75mg/kg as the G1808V2721F line while 334 
CQ sensitivity was completely restored (Figure 4E). This provided further experimental evidence, 335 
that the drug susceptibility profiles observed were due to the V2721F or V2752F amino acid 336 
substitutions and not the introduced silent mutations or secondary mutations that may have been 337 
acquired during the pre-emptive drug exposure. Interestingly, cloning and sequencing of the G1919 338 
(Figure 4B, 4F) line revealed successful introduction of the silent mutations (PAM mutating and 339 
SnaBI) while the V2721F mutation was absent in all four clonal lines, yet retained the parental 340 
V2752F mutation. This suggested that introduction of the V2721F in the V2752F background is lethal 341 
or refractory in the parasite and further supported our failed first attempt to generate the double 342 
mutant line (Figure 1). Detailed sequence analysis of the transfected parasite populations before 343 
cloning revealed the presence of only one mutation trace in the G1919 line (despite the donor DNA 344 
containing both mutations) confirming that the double mutant parasites do not survive or are 345 
severely growth-impaired and quickly overgrown by the single mutation parasites (Figure 4G). 346 
 347 
Discussion 348 
Ubiquitin hydrolases or deubiquitinating enzymes (DUBs) are essential elements of the eukaryotic 349 
ubiquitin proteasome system (UPS) which is primarily involved in maintaining cellular protein 350 
homeostasis and responding to stress. Despite the proposed involvement of Plasmodium DUBs in 351 
modulating susceptibility to multiple drugs, lack of conclusive experimental evidence has thus far 352 
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limited studies into their detailed involvement in mode of action and or resistance phenotypes such 353 
as those observed with ARTs. In this study, using a CRISPR-Cas9 mediated reverse genetics approach; 354 
we have provided experimental evidence on the direct involvement of a DUB (UBP-1) in modulating 355 
parasite responses to ART and CQ, more importantly under in vivo conditions. As the debate into the 356 
mechanism of action and resistance to ARTs continues, a consensus understanding is converging 357 
that ART resistance is more complex as several factors, genetic determinants and possibly 358 
mechanisms of action appear to be involved. In P. falciparum, ART resistance is confined to early ring 359 
stage parasites which has been translated in laboratory conditions to increased survival in ring stage 360 
survival assays (RSAs) (6). Mutations in Pfkelch13, PfCoronin as well as transient (hypo-hyperthermic) 361 
temperatures have all been shown to enhance ring stage parasite survival in the RSAs (10, 30, 31). 362 
More recently, characterisation of Kelch-13 interacting factors has revealed that disruption of 363 
proteins that co-localise with Kelch -13 such as the parasites endocytosis protein ESP15, UBP-1 and 364 
others of unknown function, modulate susceptibility to ARTs (32). As demonstrated in this study, 365 
ART and, more so, CQ reduced susceptibility can be mediated by mutations in UBP-1 underscoring a 366 
potential mechanism of cross-resistance and some commonality in mode of action between CQ and 367 
ART especially relating to haemoglobin digestion and trafficking in malaria parasites (32-34). 368 
 369 
The UBP-1 V2728F mutation was previously designated as a principle determinant of ART reduced 370 
susceptibility despite its common fixation with mefloquine and higher doses of CQ (12). Contrary to 371 
this argument, ART did not enrich for this mutation (V2752F) in our study enriching for the V2721F 372 
mutation instead which was fixed with artesunate in P. chabaudi.  However, enrichment of the 373 
V2752F mutation with a higher dose of CQ was achieved showing that this mutation does indeed 374 
modulate parasite responses to CQ while the V2721F mutation is chiefly responsible for the ART 375 
reduced susceptibility phenotype in the P. berghei model in vivo. Interestingly, drug challenge of 376 
these mutant lines in vivo revealed that both mutations give low-level cross-protection to both ARTs 377 
and CQ.  This confirms that both of these UBP-1 mutations modulate some form of protection to 378 
both ARTs and CQ drug challenges albeit to some differing degrees which is, therefore, in strong 379 
agreement with previous observations in P. chabaudi (12). This also demonstrates a plurality of 380 
pathways to resistance involving the same target. Recently, the exact equivalent UBP-1 mutations in 381 
P. falciparum, V3275F and V3306F have been successfully engineered (15).  In P. falciparum UBP-1, 382 
the V3275F mutation (V2721F P. berghei equivalent) shows enhanced survival to DHA in RSAs but 383 
remains sensitive to CQ. However, unlike in P. berghei, the V3306F (V2752F P. berghei equivalent) 384 
showed no enhanced survival to DHA in RSAs or resistance to CQ (15). Whilst not entirely in 385 
agreement with the data reported here, this could be due to limitations in the ability of in vitro 386 
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assays to fully predict actual drug responses in vivo which our data highlights and has been the 387 
concern with Kelch-13 mutations recently (35).  These observations may also somewhat be 388 
confounded by species specific differences in drug responses, pharmacodynamics, modes of action 389 
and resistance that, in part, remain to be fully investigated.  For example, previous and original 390 
linkage studies in P. chabaudi identified additional mutations in an amino acid transporter (pcaat) as 391 
being strongly  associated with CQ resistance phenotypes in tandem with UBP-1 mutations (12). 392 
Even though this could partly explain the observed in vitro sensitivity of P. falciparum V3275F 393 
mutants to CQ, our data suggests that UBP-1 mutations are sufficient to mediate quantifiable 394 
protective phenotypes to both ARTs and CQ as the reversal of the V2752F mutation performed in 395 
this study, for example, completely restores CQ sensitivity. This has provided, therefore, additional 396 
independent evidence on the direct causative role of UBP-1 mutations in modulating parasite 397 
responses not just to ARTs, but CQ as well. The study also illustrates the potential of the P. berghei 398 
rodent model in proving causality to antimalarial drug resistance phenotypes under in vivo 399 
conditions especially in light of recent reported discrepancies between some in vitro RSA resistance 400 
profiles of P. falciparum Kelch-13 mutants and actual in vivo phenotypes using the Autos monkey 401 
model (35).  402 
 403 
Interestingly, the V2721F and V2752F mutation carrying parasites are characteristically slow growing 404 
and are easily outcompeted in the presence of non-mutants. Natural P. falciparum UBP-1 mutations 405 
have been reportedly associated with ART treatment failure in Kenya (16, 19), SEA (18) and more 406 
recently in Ghana (17) (Supplementary Figure 4). However, unlike their rodent counterparts which 407 
associate with ART reduced susceptibility, the natural reported E1528D and D1525E mutations occur 408 
towards the less conserved N-terminus of the protein and outwith the conserved, bioinformatically 409 
predicted UBP-1 catalytic domain (11) (supplementary Figure 1). This would suggest that acquisition 410 
of the mutations at the well conserved C-terminal in P. falciparum has a potential growth defect as 411 
we have observed with P. berghei in this study. However, as these upstream mutations are not 412 
conserved between P. falciparum and P. berghei UBP-1, we cannot test the hypothesis in this model.  413 
In fact, P. falciparum UBP-1 is highly polymorphic with over 480 reported single nucleotide 414 
polymorphisms (SNPs) https://plasmodb.org all of which are in the N-terminal region.  PfUBP-1 has 415 
also been recently shown to be undergoing a strong positive selection in SEA (36). UBP-1 mutations 416 
could, therefore, be an independent avenue to which ART or multidrug resistance phenotypes could 417 
emerge in endemic regions like has been seen in Africa (Ghana and Kenya), without actually 418 
requiring a permissive genetic background as seems to be the current landscape with Kelch-13 419 
mutations.  However, there are constraints upon the evolution of drug resistance and UBP-1.  Whilst 420 
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these data confirm that a single protein that does not transport drugs can mediate resistance to two 421 
quite distinct drug entities, it was not possible to generate a P. berghei line that simultaneously 422 
contained the two UBP-1 drug resistance mutations examined in this study.   423 
 424 
In yeast, UBP-1 localises to the endoplasmic reticulum playing roles in protein transport specifically 425 
internalisation of substrates across membranes (37). Mutations in UBP-1 could, therefore, modulate 426 
endocytosis of important essential host derived products such as haemoglobin to the digestive 427 
vacuole in a similar manner thereby reducing exposure of the parasite to activated drug for both 428 
ARTs and CQ. Interestingly, mutations in the AP2 adaptor complex that is involved in clathrin 429 
mediated endocytosis have also been implicated in ART resistance in rodent malaria parasites (14). 430 
One of the AP2 adaptor complex mutation (I592T) has been recently engineered in P. falciparum and 431 
has been shown to enhance ring stage parasite survival in RSAs (15). This further suggests that 432 
inhibition of the endocytic trafficking system is a possible generic mechanism for the parasites to 433 
survive lethal doses of drugs that require transport and activation in the digestive vacuole. This 434 
would further explain the multidrug resistance phenotype observed with the UBP-1 mutations in P. 435 
chabaudi and P. berghei in this study. Acquisition of the V2728F mutation in P. chabaudi was 436 
structurally predicted to reduce deubiquitination (11). In such a situation, the cellular increase in 437 
ubiquitinated proteins would be anticipated to positively feedback to the cellular machinery to 438 
rapidly degrade protein substrates at the 20s proteasome promoting a non-specific and rapid 439 
protein turnover or impaired substrate trafficking. This would result in generally slow growing 440 
parasites with reduced expression of, for example, multi-drug resistance transporters as well as 441 
reduced endocytosis of host-derived products like haemoglobin, which would in turn modulate 442 
parasite responses to these drugs. More recently, functional studies have revealed that PfKelch13 443 
(known determinant of ART resistance) localises to the parasite cytosomes and plays a role in 444 
haemoglobin trafficking (32, 34). Consequently, PfKelch13 mutations have been shown to lead  to a 445 
partial loss of PfKelch13 protein function leading to decreased haemoglobin trafficking to the 446 
parasite digestive vacuole and less DHA activation which in turn mediates parasite survival (32, 34). 447 
Strikingly, protein pulldowns at the parasite cytostomal foci where Kelch-13 localises have identified 448 
UBP-1 as a key interacting partner in the Kelch-13 mediated endocytic machinery that is involved in 449 
haemoglobin trafficking. By analysing haemoglobin endocytosis in ring and trophozoite stages,  it has 450 
been demonstrated that partial inactivation of UBP-1 impairs haemoglobin endocytosis in both rings 451 
and trophozoites as opposed to inactivation of Kelch-13 which impairs haemoglobin uptake in ring 452 
stages of the parasites only (32).   This is indeed in agreement with our hypothesis and observed P. 453 
berghei phenotypes on the consequences of UBP-1 mutations which in a similar manner could 454 
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impair trafficking of haemoglobin leading to less activation of ARTs and CQ. Moreover, the potential 455 
role of UBP-1 in trafficking haemoglobin in both rings and trophozoites would possibly explain the 456 
ART and CQ potential cross-resistance phenotype, which we have observed with UBP-1 mutations; 457 
unlike with Kelch-13 mutations which thus far, are known to mediate resistance to ARTs only and in 458 
early ring stages.  The experimental validation on the involvement of UBP-1 mutations in mediating 459 
potential cross-resistance to ART and CQ in malaria parasites, therefore, provides an additional 460 
understanding of drug resistance in malaria parasites, specifically for compounds that require access 461 
and/or activation in the digestive vacuole.  Furthermore, the P. berghei model provides a useful 462 
sensitive and robust system in which to investigate the interplay and impact of simultaneous 463 
mutations of both Kelch-13 and UBP-1 in vivo as well as assess whether PfKelch13 mutations would 464 
modulate responses to CQ under in vivo conditions. 465 
 466 
In conclusion, the work presented here provides further experimental evidence for the involvement 467 
of conserved mutations in a polymorphic ubiquitin hydrolase protein that serves as a nexus for 468 
resistance to two very diverse classes of drugs.  The findings also underscore the potential difficulties 469 
that in vitro assays may have in appropriately assigning mutant parasites with appropriate 470 
phenotypes in absence of conclusive in vivo measurements. P. berghei should therefore, be a 471 
suitable and adaptable in vivo model for the rapid evaluation and/or genetic engineering of 472 
mutations associated with human-infectious Plasmodium drug resistance observed in the field for 473 
concurrent assigning of drug resistance phenotypes under both in vitro and in vivo conditions. 474 
 475 
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Figure legends   646 
Figure 1: Introduction of UBP-1 mutations in P. berghei.  647 
A. Schematic plasmid constructs for the UBP-1 targeted gene editing to introduce the V2721F and 648 
V2752F mutation. The plasmid contains Cas9 and hdhfr (for pyrimethamine drug selection) under 649 
the control of the Pb EF-1α promoter and the sgRNA expression cassettes under the control of PyU6 650 
promoter. A 20bp guide RNA was designed and cloned into sgRNA section of the vector illustrated in 651 
A. The donor UBP-1 sequence (610bp) is identical to the wild type albeit with the desired mutations 652 
of interest as indicated by coloured star symbols: V2752F (pG945), V2721F V2752F (pG946) and 653 
silent mutations that mutate the Cas9 binding site as well as introduce the restriction site BseYI for 654 
RFLP analysis. B.  Illustrated 20bp sgRNA and RFLP analysis of mutant parasites. Successful editing in 655 
the transfected parasites was observed on day 12 after transfection and pyrimethamine drug 656 
selection. RFLP (BseYI digestion) analysis of the transformed lines PCR products (primers GU4894 + 657 
GU4895, 807bp) revealed ~0.5 % and ~22 % efficiency for the G1807 and G1808 lines respectively as 658 
indicated by 2 distinct bands (536bp, 271bp) as compared to 807bp bands in the parent 820 line. C. 659 
pre-emptive challenge of the G1807 and G1808 lines with ART and CQ at 20mg/kg and 15mg/kg 660 
respectively and RFLP analysis of recrudescent parasites. Mice were infected with ~2 x 10^7 661 
parasites IP on day 0. Treatment was started ~4 hours post infection by IP for three consecutive days. 662 
Parasitaemia was monitored by microscopy analysis until recrudescence was observed. D. Pre-663 
emptive challenge of the G1807 line with higher doses of CQ and RFLP (BseYI digestion) analysis of 664 
the G1807 recrudescent population after challenge with 30mg/kg CQ. E. RFLP analysis of the cloned 665 
G1808 and G1807 ART and CQ challenged recrudescent parasites. F. DNA sequencing confirming 666 
successful nucleotide editing for the G1807 clone2 and G1808 clone1 line. The top sequence 667 
represents the 820WT unedited sequence with positions for sgRNA, protospacer adjacent motif (PAM) 668 
and V2721F or V2752F mutations indicated. The bottom sequence illustrates the nucleotide 669 
replacements at V2721F or V2752F mutation locus and silent mutations to prevent Cas9 retargeting 670 
as well as introduce the BseYI restriction site for RFLP analysis in the G1807V2752F and G1808V2721F 671 
lines. 672 
 673 
 674 
 675 
 676 
 677 
 on June 3, 2020 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
22 
 
Figure 2: ART and CQ in vitro and in vivo resistance profiles of the G1807V2752F and G1808V2721F lines.  678 
DHA dose response curves and IC50 comparisons of the G1808
V2721F (A) and G1807V2752F (B) lines 679 
relative to the wild type 820 line. CQ dose response curves and IC50 comparisons of the G1807
V2752F 680 
(C) and G1808V2721F (D) lines relative to the wild type 820 line. Significant differences between mean 681 
IC50s or IC50 shifts were calculated using the paired t-test. Error bars are standard deviations from 682 
three biological repeats. Significance is indicated with asterisks; *p < 0.05, **p < 0.01, ***p < 0.001, 683 
****p < 0.0001, ns; not significant. Modified Peters’ 4 day suppressive test to monitor resistance to 684 
ART and CQ in vivo in the G1808V2721F (E) and the G1807V2752F (F) mutant lines. Groups of three mice 685 
were infected with 1 x 106 parasites on day 0. Treatment started ~1.5 hours later with indicated drug 686 
doses every 24 hours for three consecutive days (treatment days shown by arrows). Parasitaemia 687 
was monitored by microscopy analysis of Giemsa stained blood smears up to day 18. Error bars are 688 
standard deviations of parasitaemias from 3 mice. 689 
 690 
Figure 3: Growth kinetics of the 820, G1808V2721F and G1808V2752F relative to the 1804cl1 line. The 691 
1804cl1 line constitutively expresses mCherry under the control of the hsp70 promoter.  The 820, 692 
G1808V2721F and G1808V2752F were mixed with the 1804cl1 at a 1:1 ratio and injected at a 693 
parasitaemia of 0.01% intravenously on Day 0. Daily percentages of representative parasitaemia of 694 
the 820 or mutant lines in the competition mixture were quantified by subtracting the total 695 
parasitaemia based on positivity for Hoescht DNA stain from the fraction of the population that is 696 
mCherry positive (1804cl1) as determined by flow cytometry. On day 4, when parasitaemia was ~5%, 697 
blood from each mouse was passaged into new naïve host and parasitaemia was monitored until 698 
day 8. Percentage population changes of the mutant and wild type lines relative to the 1804cl1 in 699 
the 820 (A), G1808V2721F (B) and G1807V2752F (C). Error bars are standard deviations from three 700 
biological repeats. 701 
 702 
Figure 4: Swapping of the V2752F to V2721F mutations and attempted generation of a double 703 
mutant in the G1807
V2752F
 line.  704 
A. Schematic of the UBP-1 donor DNA in the pG962 and pG963 vectors, a 20bp guide RNA used to 705 
target the UBP-1 region upstream of the V2721F mutation in the Cas9 expressing vectors with 706 
introduced silent mutation sites indicated, RFLP (SnaBI digestion) analysis of PCR products (GU5186 707 
+ GU4895, 946bp) of the G1918 and G1919 lines relative to the mutants showing successful editing 708 
by 2 distinct RFLP bands for the mutants (632bp, 314bp) and residual traces of the parental 709 
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genotype. B. RFLP analysis of the cloned G1918 and G1919 lines. First six lanes to the left are RFLP 710 
analyses of G1918 and G1919 cloned lines PCR products (GU5186 + GU4895, 946bp) digested by 711 
SnaBI showing 2 bands (632bp, 314bp) as compared to 1 band for the parental G1807
V2752F
. Six lanes 712 
to the right are the same clones digested by both SnaBI and BseYI showing parental G1807V2752F with 713 
2 RFLP bands (536bp, 410bp) as a result of digestion with BseYI only as the SnaBI restriction site is 714 
absent and 3 RFLP bands (536bp, 314bp, 96bp) in the G1918, G1919 clones as a result of digestion of 715 
the PCR product by both BseYI and SnaBI. C. Sequencing of G1918 clone1 showing successful 716 
swapping of the V2752F in the parent G1807
V2752F
 line to the V2721F mutation. D. In vitro DHA and 717 
CQ dose response curves and IC50 comparisons of the G1918cl1 revertant line relative to the wild 718 
type showing reversion of the CQ phenotype and similar sensitivity to DHA. Significant differences 719 
between mean IC50s or IC50 shifts were calculated using the paired t-test. Error bars are standard 720 
deviations from three biological repeats. Significance is indicated with asterisks; *p < 0.05, **p < 0.01, 721 
***p < 0.001, ****p < 0.0001, ns; not significant. E.  In vivo tolerance to ARTs at 75mg/kg in the 722 
G1918cl1 line and complete restoration of CQ sensitivity. Sequence analysis of the G1919 clone 1 (F) 723 
line and G1919 (G) uncloned line showing absence of double mutant populations. 724 
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Figure 3 802 
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Figure 4 817 
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